MRK

ACCE-researched
Merck & Company Inc. Common Stock (new)
Healthcare · Drug Manufacturers - General · NYSE · United States
$146.87-0.19%
Market cap $362.4BNext earnings 2026-10-29Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$146.87+0.0%
confidence-weighted across 5 of 6 models
Now $146.87
$146.87
$52.23$113.96
AvoidBronze51
Price vs fair value
93.7% above
-48.4% to fair value
ACCE score
54
out of 100
Analysts
58% buy
26 covering
P/E
117.5x
forward 15.2x
1-year return
+80.1%
Dividend yield
2.26%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 3 flags
  • high
    Earnings decline severe
    Earnings YoY down 19.3% despite revenue growing 4.9%, signaling significant margin compression at the net income level.
  • moderate
    Net margin compression
    Net margin at 13.6% appears low relative to 76.7% gross margin, suggesting heavy below-gross-profit costs eroding profitability.
  • moderate
    Growth score weak
    ACCE Growth score of 28/100 is notably poor, consistent with earnings decline and near-flat QoQ revenue of -0.7%.
Reports in 37 days, last quarter beat by 0.5%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+82.7% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Mixed58% buy · 26 covering analysts
● Strong buy 12● Buy 3● Hold 11● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 21.0x117.5xhigh 117.5x
ROEbetter than 0% of peers
low 7%7%high 91%
Div yieldbetter than 17% of peers
low 1.9%2.3%high 4.0%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
ABBVAbbVie Inc. Common Stock$466.4B74.662.3%-20.912.6%-Compare
NVSNovartis AG Common Stock$266.8B21.230.3%0.733.4%-Compare
NOVN.SWNovartis$265.0B21.030.3%0.734.0%-Compare
AZN.LAstraZeneca$258.7B25.022.0%0.572.6%-Compare
AZNAstraZeneca PLC Ordinary Shares$257.6B24.922.0%0.571.9%-Compare
AMGNAmgen Inc. Common Stock$208.5B24.091.5%6.312.6%-Compare

Sector report card

Where MRK ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 37 days, last quarter beat by 0.5%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+2.0%
1 month
-3.5%
3 months
+29.0%
6 months
+28.6%
YTD
+39.5%
1 year
+80.1%

SEC filings

40 filings
August 2026
Aug 13
Form 4Insider transactionPeriod 2026-08-13
Aug 13
Form 4Insider transactionPeriod 2026-08-12
Aug 12
Form 4Insider transactionPeriod 2026-08-10
37 more filings + AI summaries on Investor+.INVESTOR